EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients

Kay Choong See

World Journal of Diabetes · 15.06.2024 · 15 (6) · 1178-1186

DOI: 10.4239/wjd.v15.i6.1178 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Diabetes, online erschienen am 15.06.2024. Verfasst von Kay Choong See. Beteiligte Einrichtung: Department of Medicine, National University Hospital, Singapore 119228, Singapore. kaychoongsee@nus.edu.sg. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is a common diabetes drug that may reduce lactate clearance by inhibiting mitochondrial oxidative phosphorylation, leading to metformin-associated lactic acidosis (MALA). As diabetes mellitus is a common chronic metabolic condition found in critically ill patients, pre-existing metformin use can often be found in critically ill patients admitted to the intensive care unit or the high dependency unit. The aim of this narrative mini review is therefore to update clinicians about MALA, and to provide a practical approach to its diagnosis and treatment. MALA in critically ill patients may be suspected in a patient who has received metformin and who has a high anion gap metabolic acidosis, and confirmed when lactate exceeds 5 mmol/L. Risk factors include those that reduce renal elimination of metformin (renal impairment from any cause, histamine-2 receptor antagonists, ribociclib) and excessive alcohol consumption (as ethanol oxidation consumes nicotinamide adenine dinucleotides that are also required for lactate metabolism). Treatment of MALA involves immediate cessation of metformin, supportive management, treating other concurrent causes of lactic acidosis like sepsis, and treating any coexisting diabetic ketoacidosis. Severe MALA requires extracorporeal removal of metformin with either intermittent hemodialysis or continuous kidney replacement therapy. The optimal time to restart metformin has not been well-studied. It is nonetheless reasonable to first ensure that lactic acidosis has resolved, and then recheck the kidney function post-recovery from critical illness, ensuring that the estimated glomerular filtration rate is 30 mL/min/1.73 m2 or better before restarting metformin.

Schlagwörter

Stichwörter der Autor:innen

Acid-base equilibriumBiguanidesOxidative phosphorylationPyruvic acidRenal replacement therapy

Autor:innen und Institutionen

  • Department of Medicine, National University Hospital, Singapore 119228, Singapore. kaychoongsee@nus.edu.sg.

Zitieren

APA

See, K. C. (2024). Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients. World Journal of Diabetes, 15(6), 1178-1186. https://doi.org/10.4239/wjd.v15.i6.1178

Vancouver

See KC. Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients. World Journal of Diabetes. 2024;15(6):1178-1186. doi:10.4239/wjd.v15.i6.1178

BibTeX
@article{See2024,
  author = {See, Kay Choong},
  title = {Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients},
  journal = {World Journal of Diabetes},
  year = {2024},
  volume = {15},
  number = {6},
  pages = {1178--1186},
  doi = {10.4239/wjd.v15.i6.1178}
}
Kostenlos starten →